Liquidia is actively seeking life science partners to collaborate with and/or license its PRINT® technology to enhance drug design and development activities across a range of therapeutic areas, molecule types, and routes of administration.
PRINT particles can be designed to help partners address targeted pharmacological goals such as optimizing the route of administration, improving solubility and enhancing stability. PRINT-enabled products have the potential to improve safety, convenience, and clinical results for patients. Additionally, Liquidia’s leadership team and investors bring extensive drug development and leadership experience across medicine, academia and pharmaceuticals.
Please fill out this form if you are interested in working with us. We look forward to hearing from you!